These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2885865)

  • 1. Rebound insomnia in neuroleptic drug withdrawal neurophysiologic characteristics.
    van Sweden B
    Pharmacopsychiatry; 1987 May; 20(3):116-9. PubMed ID: 2885865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebound insomnia: duration of use and individual differences.
    Merlotti L; Roehrs T; Zorick F; Roth T
    J Clin Psychopharmacol; 1991 Dec; 11(6):368-73. PubMed ID: 1770156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena.
    Bianchi M; Musch B
    Int Clin Psychopharmacol; 1990 Apr; 5 Suppl 2():139-45. PubMed ID: 2387981
    [No Abstract]   [Full Text] [Related]  

  • 4. Rebound insomnia: a critical review.
    Gillin JC; Spinweber CL; Johnson LC
    J Clin Psychopharmacol; 1989 Jun; 9(3):161-72. PubMed ID: 2567741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utilization of hypnotics in chronic schizophrenics: some critical remarks.
    Jus K; Jus A; Villeneuve A; Pires P; Fontaine P
    Biol Psychiatry; 1979 Dec; 14(6):955-60. PubMed ID: 41605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term efficacy and withdrawal of zopiclone: a sleep laboratory study.
    Pecknold J; Wilson R; le Morvan P
    Int Clin Psychopharmacol; 1990 Apr; 5 Suppl 2():57-67. PubMed ID: 2117623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound insomnia after abrupt clozapine withdrawal.
    Staedt J; Stoppe G; Hajak G; Ruther E
    Eur Arch Psychiatry Clin Neurosci; 1996; 246(2):79-82. PubMed ID: 9063912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.
    Lemoine P; Nir T; Laudon M; Zisapel N
    J Sleep Res; 2007 Dec; 16(4):372-80. PubMed ID: 18036082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal from clozapine: the "rebound phenomenon".
    Durst R; Teitelbaum A; Katz G; Knobler HY
    Isr J Psychiatry Relat Sci; 1999; 36(2):122-8. PubMed ID: 10472746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal symptoms after long-term treatment with low-potency neuroleptics.
    Chouinard G; Bradwejn J; Annable L; Jones BD; Ross-Chouinard A
    J Clin Psychiatry; 1984 Dec; 45(12):500-2. PubMed ID: 6150030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena.
    Bhanji NH; Chouinard G; Kolivakis T; Margolese HC
    Can J Clin Pharmacol; 2006; 13(1):e69-74. PubMed ID: 16456219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects.
    Lader M; Frcka G
    Pharmacopsychiatry; 1987 Mar; 20(2):67-71. PubMed ID: 2884682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebound insomnia induced by abrupt withdrawal of hypnotics in sleep-disturbed rats.
    Hirase M; Ishida T; Kamei C
    Eur J Pharmacol; 2008 Nov; 597(1-3):46-50. PubMed ID: 18789918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REM-latency in neuroleptic drug withdrawal. A case report.
    Van Sweden B
    Acta Psychiatr Belg; 1984; 84(3):235-9. PubMed ID: 6148841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW; Bystritsky A
    J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: two case reports.
    Sovner R
    Ment Retard; 1995 Aug; 33(4):221-5. PubMed ID: 7565144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The risk of neuroleptic discontinuation in schizophrenia].
    Jarema M
    Psychiatr Pol; 1999; 33(1):69-81. PubMed ID: 10786216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
    Roth T; Seiden D; Sainati S; Wang-Weigand S; Zhang J; Zee P
    Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing new neuropsychotropic drugs--focus on hypnotics.
    Koella WP
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):623-9. PubMed ID: 6131494
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study.
    Nishikawa T; Hayashi T; Koga I; Uchida Y
    Psychiatry; 2007; 70(1):68-79. PubMed ID: 17492913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.